^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    dinaciclib (MK-7965)

    i
    Company:
    Ligand, Merck (MSD)
    Drug class:
    CDK inhibitor
    Related drugs:
    Apply
    Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors (NCT01434316)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    11/11/2011
    Primary completion :
    03/28/2023
    Completion :
    08/02/2025
    BRCA1 • BRCA2 • BRCA • RAD51
    |
    BRCA mutation
    |
    veliparib (ABT-888) • dinaciclib (MK-7965)
    Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer (NCI-2018-01053) (NCT01676753)
    Phase 1b
    Jo Chien
    Completed
    Last update posted :
    09/21/2022
    Initiation :
    12/28/2016
    Primary completion :
    06/30/2020
    Completion :
    02/28/2022
    PGR
    |
    PGR expression
    |
    Keytruda (pembrolizumab) • dinaciclib (MK-7965)
    Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer (NCT01624441)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    03/30/2018
    Initiation :
    08/21/2012
    Primary completion :
    09/10/2013
    Completion :
    09/10/2013
    HER-2 • ER • PGR • MCL1
    |
    HER-2 amplification • HER-2 negative
    |
    epirubicin • dinaciclib (MK-7965)
    SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) (NCT00732810)
    Phase 2
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    08/05/2015
    Initiation :
    07/01/2008
    Primary completion :
    06/01/2011
    Completion :
    06/01/2011
    HER-2
    |
    HER-2 positive
    |
    erlotinib • capecitabine • dinaciclib (MK-7965)